|
|
Volumn 33, Issue 1-2, 2001, Pages 1019-1020
|
|
Tacrolimus (FK 506) in kidney transplantation: Five-year survival results of the U.S. multicenter, randomized, comparative trial
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIHYPERTENSIVE AGENT;
ANTILIPEMIC AGENT;
AZATHIOPRINE;
CYCLOSPORIN;
LYMPHOCYTE ANTIBODY;
OKT 3;
PREDNISONE;
TACROLIMUS;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
FOLLOW UP;
GRAFT SURVIVAL;
HUMAN;
KIDNEY GRAFT REJECTION;
MAJOR CLINICAL STUDY;
MULTICENTER STUDY;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RISK BENEFIT ANALYSIS;
RISK FACTOR;
TREATMENT FAILURE;
CROSS-OVER STUDIES;
CYCLOSPORINE;
DRUG RESISTANCE;
FOLLOW-UP STUDIES;
GLUCOCORTICOIDS;
GRAFT REJECTION;
GRAFT SURVIVAL;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY TRANSPLANTATION;
PREDNISONE;
TACROLIMUS;
|
|
EID: 0035082211
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(00)02312-5 Document Type: Conference Paper |
|
Times cited : (29)
|
|
References (2)
|
